Table 4

Best tumor response per RECIST v.1.1 in evaluable patients* who had at least one post-baseline disease assessment (pacmilimab 10 mg/kg dose-escalation and expansion phases)

Other tumor types (n=12)TNBC
(n=15)
Anal SCC (n=15)cSCC
(n=14)
UPS
(n=20)
SBA
(n=14)
TET
(n=10)
hTMB
(n=14)
Pacmilimab 10 mg/kg
total (n=114)
ORR†, % (95% CI)8
(0.2–39)
7
(0.2–32.0)
13
(2–41)
36
(13–65)
5
(0.1–25)
0
(0–23)
0
(0–31)
29
(8–58)
12
(7–20)
 Complete response, n (%)0001 (7)0001 (7)2 (2)
 Partial response, n (%)1 (8)1 (7)2 (13)4 (29)1 (5)003 (21)12 (11)
Stable disease, n (%)3 (25)7 (47)6 (40)5 (36)4 (20)2 (14)5 (50)2 (14)34 (30)
Disease control rate‡, n (%)4 (33)8 (53)8 (53)10 (71)5 (25)2 (14)5 (50)6 (43)48 (42)
Progressive disease, n (%)7 (58)5 (33)7 (47)4 (29)12 (60)9 (64)4 (40)5 (36)53 (47)
Discontinued early§, n (%)1 (8)2 (13)003 (15)3 (21)1 (10)3 (21)13 (11)
  • *Treated patients who had an adequate baseline assessment.

  • †ORR is the sum of the confirmed partial and complete responses.

  • ‡Disease control rates is the sum of the complete responses, partial responses, and stable disease.

  • §Patients who discontinued the study without a post-baseline tumor assessment.

  • cSCC, cutaneous squamous cell carcinoma; hTMB, high tumor mutational burden; ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors; SBA, small bowel adenocarcinoma; SCC, squamous cell carcinoma; TET, thymic epithelial tumor; TNBC, triple-negative breast cancer; UPS, undifferentiated pleiomorphic sarcoma.